Bioinformatics Study on Serum Triglyceride Levels for Analysis of a Potential Risk Factor Affecting Blood Pressure Variability

Author(s): Lin Xu, Jiangming Huang, Zhe Zhang, Jian Qiu, Yan Guo, Hui Zhao, Zekun Cai, Xiaomin Huang, Yongwang Fan, Yehao Xu, Jun Ma*, Wanqing Wu*.

Journal Name: Current Bioinformatics

Volume 14 , Issue 5 , 2019

Submit Manuscript
Submit Proposal

Graphical Abstract:


Abstract:

Objective: The purpose of this study was to establish whether Triglycerides (TGs) are related to Blood Pressure (BP) variability and whether controlling TG levels leads to better BP variability management and prevents Cardiovascular Disease (CVD).

Methods: In this study, we enrolled 106 hypertensive patients and 80 non-hypertensive patients. Pearson correlation and partial correlation analyses were used to define the relationships between TG levels and BP variability in all subjects. Patients with hypertension were divided into two subgroups according to TG level: Group A (TG<1.7 mmol/L) and Group B (TG>=1.7 mmol/L). The heterogeneity between the two subgroups was compared using t tests and covariance analysis.

Results: TG levels and BP variability were significantly different between the hypertensive and non-hypertensive patients. Two-tailed Pearson correlation tests showed that TG levels are positively associated with many BP variability measures in all subjects. After reducing other confounding factors, the partial correlation analysis revealed that TG levels are still related to the Standard Deviation (SD), Coefficient of Variation (CV) of nighttime systolic blood pressure and CV of nighttime diastolic blood pressure, respectively (each p<0.05). In the subgroups, group A had a lower SD of nighttime Systolic Blood Pressure (SBP_night_SD; 11.39±3.80 and 13.39±4.16, p=0.011), CV of nighttime systolic blood pressure (SBP_night_CV; 0.09±0.03 and 0.11±0.03, p=0.014) and average real variability of nighttime systolic blood pressure (SBP_night_ARV; 10.99±3.98 and 12.6±3.95, p=0.024) compared with group B, even after adjusting for age and other lipid indicators.

Conclusion: TG levels are significantly associated with BP variability and hypertriglyceridemia, which affects blood pressure variability before causing target organ damage.

Keywords: Triglycerides (TGs), Blood Pressure (BP) variability, Cardiovascular Disease (CVD), pearson correlation, Standard Deviation (SD), Coefficient of Variation (CV).

[1]
Floras JS. Blood pressure variability: A novel and important risk factor. Can J Cardiol 2013; 29(5): 557-63.
[2]
Rothwell PM. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet 2010; 375(9718): 938-48.
[3]
Wizner B, Dechering DG, Thijs L, et al. Short-term and long-term repeatability of the morning blood pressure in older patients with isolated systolic hypertension. J Hypertens 2008; 26(7): 1328-35.
[4]
Hansen TW, Thijs L, Li Y, et al. Prognostic value of reading-to-reading blood pressure variability over 24 hours in 8938 subjects from 11 populations. Hypertension 2010; 55(4): 1049-57.
[5]
Pringle E, Phillips C, Thijs L, et al. Systolic blood pressure variability as a risk factor for stroke and cardiovascular mortality in the elderly hypertensive population. J Hypertens 2003; 21(12): 2251-7.
[6]
Davidson MB, Vidt DG, Hoogwerf BJ, Brotman DJ. Relation of diurnal blood pressure variation and triglyceride-to-high-density lipoprotein cholesterol ratio in patients without diabetes mellitus. Am J Cardiol 2005; 95(1): 123-6.
[7]
Parati G, Ochoa JE, Lombardi C, Bilo G. Assessment and management of blood-pressure variability. Nat Rev Cardiol 2013; 10(3): 143-55.
[8]
Parati G, Omboni S, Rizzoni D, Agabiti-Rosei E, Mancia G. The smoothness index: A new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. J Hypertens 1998; 16(11): 1685-91.
[9]
Rizzoni D, Muiesan ML, Salvetti M, et al. The smoothness index, but not the trough-to-peak ratio predicts changes in carotid artery wall thickness during antihypertensive treatment. J Hypertens 2001; 19(4): 703-11.
[10]
Jafar TH, Ebrahim SB. Variations in levels of blood pressure: of prognostic value or not? Am J Kidney Dis 2008; 52(4): 638-41.
[11]
Mancia G. Short- and long-term blood pressure variability: present and future. Hypertension 2012; 60(2): 512-7.
[12]
Parati G, Ochoa JE, Salvi P, Lombardi C, Bilo G. Prognostic value of blood pressure variability and average blood pressure levels in patients with hypertension and diabetes. Diabetes Care 2013; 36(Suppl. 2): S312-24.
[13]
Parati G. Blood pressure variability: its measurement and significance in hypertension. J Hypertens Suppl 2005; 23(1): S19-25.
[14]
Schillaci G, Bilo G, Pucci G, et al. Relationship between short-term blood pressure variability and large-artery stiffness in human hypertension: findings from 2 large databases. Hypertension 2012; 60(2): 369-77.
[15]
Lin SX, Carnethon M, Szklo M, Bertoni A. Racial/ethnic differences in the association of triglycerides with other metabolic syndrome components: the Multi-Ethnic Study of Atherosclerosis. Metab Syndr Relat Disord 2011; 9(1): 35-40.
[16]
Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet 2014; 384(9943): 626-35.
[17]
Wang X, Ye P. GW26-e2209 Plasma Triglyceride is a predictive factor for arterial stiffness: a community-based 4.8-year prospective study Abstract. J Am Coll Cardiol 2015; 66(Suppl. 16).
[http://dx.doi.org/10.1016/j.jacc.2015.06.444]
[18]
Do R, Willer CJ, Schmidt EM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet 2013; 45(11): 1345-52.
[19]
Kim MA. Triglyceride and cardiovascular disease. J Lipid Atheroscler 2013; 2(1): 1-8.
[20]
Tenenbaum A, Klempfner R, Fisman EZ. Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor. Cardiovasc Diabetol 2014; 13: 159.
[21]
Anantharam B, Janardhanan R, Hayat S, Senior R. Ischaemic burden determined by myocardial contrast echocardiography predicts mortality in patients with new-onset shortness of breath, suspected heart failure and no previous coronary artery disease. Int J Cardiol 2013; 168(2): 1670-1.
[22]
Liu S, Wassef AW, Moussa M, Jassal DS, Hussain F. The utility of diastolic dysfunction on echocardiography for predicting coronary artery disease burden as defined by the syntax score. Can J Cardiol 2013; 29: S304-5.
[23]
Alexandrov AV. Ultrasound and angiography in the selection of patients for carotid endarterectomy. Curr Cardiol Rep 2003; 5(2): 141-7.
[24]
Paciaroni M, Caso V, Cardaioli G, et al. Is ultrasound examination sufficient in the evaluation of patients with internal carotid artery severe stenosis or occlusion. Cerebrovasc Dis 2003; 15(3): 173-6.
[25]
Brott TG, Halperin JL, Abbara S, et al. 2011 ASA/ACCF/AHA/ AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease. A report of the American College of Cardiology Foundation/American Heart Association Task F. Circulation 2011; 124(4): 54-130.
[26]
Touboul PJ, Hennerici MG, Meairs S, et al. Mannheim carotid intima-media thickness consensus (2004-2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis 2007; 23(1): 75-80.
[27]
Xiong H, Wu D, Tian X, et al. The relationship between the 24h blood pressure variability and carotid intima-media thickness: a compared study. Comput Math Methods Med 2014; 2014303159.
[28]
Giantin V, Perissinotto E, Franchin A, et al. Ambulatory blood pressure monitoring in elderly patients with chronic atrial fibrillation: is it absolutely contraindicated or a useful tool in clinical practice and research? Hypertens Res 2013; 36(10): 889-94.
[29]
Tai C, Sun Y, Dai N, et al. Prognostic significance of visit-to-visit systolic blood pressure variability: a meta-analysis of 77,299 patients. J Clin Hypertens 2015; 17(2): 107-15.
[30]
Mena LJ, Maestre GE, Hansen TW, et al. How many measurements are needed to estimate blood pressure variability without loss of prognostic information? Am J Hypertens 2014; 27(1): 46-55.
[31]
Levitan EB, Kaciroti N, Oparil S, Julius S, Muntner P. Relationships between metrics of visit-to-visit variability of blood pressure. J Hum Hypertens 2013; 27(10): 589-93.
[32]
Zuern CS, Rizas KD, Eick C, et al. Effects of renal sympathetic denervation on 24-hour blood pressure variability. Front Physiol 2012; 3(134): 134.
[33]
Mancia G, Parati G, Hennig M, et al. Relation between blood pressure variability and carotid artery damage in hypertension: Baseline data from the european lacidipine study on atherosclerosis (ELSA). J Hypertens 2001; 19(11): 1981-9.
[34]
Mancia G, Bombelli M, Facchetti R, et al. Long-term prognostic value of blood pressure variability in the general population: Results of the Pressioni Arteriose Monitorate e Loro Associazioni Study. Hypertension 2007; 49(6): 1265-70.
[35]
Verdecchia P, Angeli F, Gattobigio R, Rapicetta C, Reboldi G. Impact of blood pressure variability on cardiac and cerebrovascular complications in hypertension. Am J Hypertens 2007; 20(2): 154-61.
[36]
Webb AJS, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: A systematic review and meta-analysis. Lancet 2010; 375(9718): 906-15.
[37]
Parati G, Ochoa JE, Lombardi C, Bilo G. Assessment and management of blood-pressure variability. Nat Rev Cardiol 2013; 10(3): 143-55.
[38]
Qiao Q. Comparison of different definitions of the metabolic syndrome in relation to cardiovascular mortality in European men and women. Diabetologia 2006; 49(12): 2837-46.
[39]
Ford ES, Li C, Zhao G, Pearson WS, Mokdad AH. Hypertriglyceridemia and its pharmacologic treatment among US adults. Arch Intern Med 2009; 169(6): 572-8.
[40]
Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298(3): 299-308.
[41]
He Y, Lam TH, Li LS, Li LS, He SF, Liang BQ. Triglyceride and coronary heart disease mortality in a 24-year follow-up study in Xi’an, China. Ann Epidemiol 2004; 14(1): 1-7.
[42]
Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007; 298(3): 309-16.
[43]
Almeda-Valdes P, Cuevas-Ramos D, Mehta R, et al. Factors associated with postprandial lipemia and apolipoprotein A-V levels in individuals with familial combined hyperlipidemia. BMC Endocr Disord 2014; 14(1): 90.
[44]
Palatini P, Reboldi G, Beilin LJ, et al. Added predictive value of night-time blood pressure variability for cardiovascular events and mortality: the Ambulatory Blood Pressure-International Study. Hypertension 2014; 64(3): 487-93.
[45]
Kawai T, Ohishi M, Kamide K, et al. Differences between daytime and nighttime blood pressure variability regarding systemic atherosclerotic change and renal function. Hypertens Res 2013; 36(3): 232-9.
[46]
Kataoka S, Okada K, Gohbara M, et al. The effect of nightime blood pressure variability on left ventricular hypertrophy and carotid intima media thickness in patients with natemi. J Am Coll Cardiol 2013; 61(Suppl. 10).
[http://dx.doi.org/10.1016/S0735-1097(13)61475-8]
[47]
Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302(18): 1993-2000.


Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 14
ISSUE: 5
Year: 2019
Page: [376 - 385]
Pages: 10
DOI: 10.2174/1574893614666190109152809
Price: $58

Article Metrics

PDF: 8